Vertex's Crinetics deal points to big ambitions for cystic fibrosis leader

July 7, 2026 02:47 PM EDT Deals Ver­tex's $10B Cri­net­ics deal marks its clear­est step yet to­ward bio­phar­ma's top ranks Max Gelman Senior Editor Ver­tex Phar­ma­ceu­ti­cals’ $10 bil­lion ac­qui­si­tion of an en­docrinol­o­gy start­up rep­re­sents the com­pa­ny’s clear­est and bold­est step to­ward the up­per ech­e­lon of the bio­phar­ma in­dus­try. Long … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER